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ABSTRACT
Background: Anti-tumour necrosis factor (TNF)a treat-
ments improve outcome in severe rheumatoid arthritis
(RA) and are efficacious in psoriasis and psoriatic arthritis.
However recent case reports describe psoriasis occurring
as an adverse event in patients with RA receiving anti-
TNFa therapy.
Objectives: We aimed to determine whether the
incidence rate of psoriasis was higher in patients with RA
treated with anti-TNFa therapy compared to those
treated with traditional disease-modifying antirheumatic
drugs (DMARDs). We also compared the incidence rates
of psoriasis between the three anti-TNFa drugs licensed
for RA.
Methods: We studied 9826 anti-TNF-treated and 2880
DMARD-treated patients with severe RA from The British
Society for Rheumatology Biologics Register (BSRBR). All
patients reported with new onset psoriasis as an adverse
event were included in the analysis. Incidence rates of
psoriasis were calculated as events/1000 person years
and compared using incidence rate ratios (IRR).
Results: In all, 25 incident cases of psoriasis in patients
receiving anti-TNFa therapy and none in the comparison
cohort were reported between January 2001 and July
2007. The absence of any cases in the comparison cohort
precluded a direct comparison; however the crude
incidence rate of psoriasis in those treated with anti-TNFa
therapy was elevated at 1.04 (95% CI 0.67 to 1.54) per
1000 person years compared to the rate of 0 (upper
97.5% CI 0.71) per 1000 person years in the patients
treated with DMARDs. Patients treated with adalimumab
had a significantly higher rate of incident psoriasis
compared topatientstreated withetanercept(IRR 4.6, 95%
CI 1.7 to 12.1) and infliximab (IRR 3.5, 95% CI 1.3 to 9.3).
Conclusions: Results from this study suggest that the
incidence of psoriasis is increased in patients treated with
anti-TNFa therapy. Our findings also suggest that the
incidence may be higher in patients treated with
adalimumab.
The cytokine tumour necrosis factor a (TNFa)i s
known to play a key role in the pathogenesis of
rheumatoid arthritis (RA),
1 and is also thought to
have a key pathophysiological role in psoriasis.
2
Psoriasis and inflammatory arthritis can coexist as
psoriatic arthritis.
3 In approximately 66% of
patients with psoriatic arthritis, psoriasis precedes
joint disease, while in equal proportions of the
remaining cases arthritis precedes the onset of
psoriasis, or both occur within 1 year of each
other.
3 Treatments that inhibit the action of TNFa
have dramatically improved outcome in severe
RA.
4–6 Anti-TNFa therapies have also been shown
to be efficacious in psoriasis
278 and psoriatic
arthritis.
9 The three anti-TNFa therapies currently
licensed for RA in the UK are etanercept, inflix-
imab and adalimumab.
Despite the evident efficacy of anti-TNFa
therapies for RA and psoriasis, several recently
published case reports describe psoriasis occurring
as an adverse event in patients with RA receiving
anti-TNFa therapy. We identified 15 studies,
which detail 41 cases of psoriasis-like adverse
events
10–24 (table 1) through a Medline search
combining the terms ‘‘anti-TNF’’, ‘‘rheumatoid
arthritis’’ and ‘‘psoriasis’’ and searching the refer-
ence lists of relevant articles. The median age of
these 41 patients was 51.5 (interquartile range
(IQR) 43.5 to 63) and the female to male ratio was
6.6:1. Many of these report incident cases of
psoriasis occurred within 9 months of starting
anti-TNFa therapy (median 6 months, IQR 2 to
17).
10–16 18 20 21 23 This temporal association points
towards possible causality. Adalimumab is cited as
frequently as infliximab and etanercept as the anti-
TNFa drug involved with these adverse events,
despite being the most recent of these three drugs
to be launched. However, published case reports
cannot determine the incidence of psoriasis as an
adverse event because the denominator is not
known. Further, they cannot determine whether
the incidence is increased by the drug beyond that
seen without anti-TNFa treatment, or whether the
incidence differs between drugs.
Using data on 9826 patients treated with anti-
TNFa with RA in the British Society for
Rheumatology Biologics Register (BSRBR), we set
out to determine whether the incidence rate of
psoriasis was higher in patients with RA treated
with anti-TNFa therapy compared to those treated
with traditional disease-modifying antirheumatic
drugs (DMARDs). Additionally we aimed to
compare the incidence rates of psoriasis between
the three anti-TNFa drugs licensed for RA.
METHODS
The patients included in this study were partici-
pants in the BSRBR, a large national prospective
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ily to monitor the safety of anti-TNFa therapies in routine
clinical practice. The methods of this study have been described
in detail previously.
25 Briefly, the first 4000 patients with RA
starting each anti-TNFa therapy were required by The National
Institute for Health and Clinical Excellence (NICE) to be
registered with the BSRBR and followed up for information on
drug use, disease activity and adverse events. In the UK,
prescription of anti-TNFa drugs is restricted to patients with
active disease (28-joint Disease Activity Score (DAS28) .5.1)
despite previous therapy with at least two disease-modifying
antirheumatic drugs (DMARDS), one of which should be
methotrexate.
26 All patients with a doctor diagnosis of RA
who were receiving etanercept, infliximab or adalimumab as
their first anti-TNFa therapy comprise the anti-TNFa cohort for
this study.
A comparison cohort of patients who were biological naive
with active RA was recruited in parallel within the BSRBR and
followed up with identical methodology. Those patients had
doctor-diagnosed RA, active disease (guideline DAS28.4.2),
current treatment with a DMARD and no previous exposure to
any anti-TNFa drug. Patients registered in the comparison
cohort could subsequently receive an anti-TNFa drug if
clinically indicated, at which point they would switch to
contributing exposure time to the anti-TNFa cohort. The TNF
treated cohort and those in the comparison cohort had to have
Table 1 Case reports of new onset psoriasis following treatment for rheumatoid arthritis with anti-tumour necrosis factor (TNF) therapy
Patient Reference Age/sex Affected areas Diagnosis Treatment
Latency,
months
1 Beuthien et al
10 63F Injection site (thigh), palms and soles Papulopustular exanthaema ADA3
2 Dereure et al
11 47F Anterior aspects of legs Psoriasis INF 2
3 Dereure et al
11 55F Palms, soles, umbilicus, ankles wrists and buttocks Psoriasis ETA 3
4 Flendrie et al
12 – Hands and feet Psoriasis/psoriaform eruption ADA 9
5 Flendrie et al
12 – Lower legs Psoriasis/psoriaform eruption ADA 48
6 Flendrie et al
12 – Arms and legs Psoriasis/psoriaform eruption ADA 16
7 Grinblat et al
13 37F Scalp, arms and legs Psoriasis INF ,1 week
8 Sfikakis et al
14 65F Palms, soles, elbows, arms and thighs Psoriasis ADA 9
9 Sfikakis et al
14 48F Soles, elbows, lower legs Psoriatic plaques ETA 7
10 Kary et al
15 41F Palms, soles, legs and arms Psoriasis vulgaris ADA 14–15
11 Kary et al
15 65F Limbs Psoriasis vulgaris ADA 4 days
12 Kary et al
15 38M Limbs and abdomen (Had family sister) Psoriasis vulgaris INF 3
13 Kary et al
15 67F Palms, arms, legs and scalp (Had family brother) Psoriasis pustulosa ADA 5
14 Kary et al
15 49F Legs and soles of feet (pre-existing but asymptomatic) Psoriasis pustulosa INF 8
15 Kary et al
15 49F Legs and arms (pre-existing but asymptomatic for 15
years)
Psoriasis pustulosa ETA 1
16 Kary et al
15 63F Extremities and trunk Psoriasis vulgaris ETA 2
17 Sari et al
16 30F Scalp, elbows, abdomen and lower back Psoriasis ETA 2
18 Goncalves et al
17 61F Hands and feet Plaque psoriasis INF 14
19 Aslanidis et al
18 64F Elbows, neck and scalp Psoriasisiform dermatitis ADA 3
20 Cohen et al
19 70F Pubis, umbilicus, legs Psoriasis INF 41
21 Cohen et al
19 63F Legs, arms Psoriasis ETA 10
22 de Gannes et al
20 41F Heel and palm Palmoplantar psoriasis ETA 26
23 de Gannes et al
20 53F Elbows Plaque psoriasis ETA 17
24 de Gannes et al
20 66F Scalp, arms, chest and neck Plaque and guttate psoriasis ETA 4
25 de Gannes et al
20 51M Elbows Psoriasis ETA 12
26 de Gannes et al
20 48F Arms and trunk Papulosquamous eruption ETA 3
27 de Gannes et al
20 41F Scalp, thigh and thumb Palmoplantar pustular psoriasis INF 2
28 de Gannes et al
20 52F Palmoplantar pustular psoriasis Palmoplantar pustular psoriasis INF2 4
29 de Gannes et al
20 78F Lesions on shins Thick surface keratin with focal
parakeratosis
INF 2
30 de Gannes et al
20 56M Palms, soles, legs Pustular psoriasis ADA 62
31 de Gannes et al
20 50M Trunk, shins and arms Psoriasis INF 12
32 de Gannes et al
20 55F Palms, soles and ankles Plaque and pustular psoriasis ADA 36
33 de Gannes et al
20 49M Palms and soles Pustular psoriasis ADA 5
34 de Gannes et al
20 37F Plantar surfaces Plaque psoriasis with subsequent
pustules
ETA 24
35 Ubriani et al
21 65F Legs, trunk and extremities Psoriasis INF 48
36 Ubriani et al
21 45F Palmoplantar pustulosis Palmoplantar pustulosis ADA 1
37 Starmans-Kool et
al
22
62F Hands and feet. Swollen hands, knees Palmoplantar pustulosis INF 5th Infusion
38 Michaelsson et
al
23
62F Palmoplantar pustulosis with lesions on legs and arms Palmoplantar pustulosis & pustular
psoriasis
INF 2 weeks
39 Michaelsson et
al
23
50F Palmoplantar pustulosis with lesions on extremities Palmoplantar pustulosis INF 1.5
40 Roux et al
24 42F Psoriatic palmoplantaris pustulosis Psoriatic palmoplantaris pustulosis INF 1.5
41 Roux et al
24 32F Plantaris pustulosis with lesions on legs, arms and trunk Psoriatic palmoplantaris pustulosis &
diffuse erythaematosquamous lesions
INF 7
ADA, adalimumab; ETA, etanercept; INF, infliximab.
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included in this analysis.
Baseline information for the BSRBR is collected from two
sources. A rheumatologist or rheumatology specialist nurse
completes a standardised form that includes demographic data
such as age, sex, diagnosis, disease duration and clinical outcome
measures including the DAS28.
27 The patients complete a
questionnaire that includes the Stanford Health Assessment
Questionnaire adapted for UK use,
28 history of smoking and
occupational history.
Follow-up questionnaires are completed by rheumatologists
(or specialist nurse) for 5 years (semiannually for the first 3
years and annually for a subsequent 2 years) and patients for 3
years. Rheumatologists are requested to provide details of
changes in therapy, current disease activity and development of
any adverse events. Adverse events are recorded regardless of
whether or not the doctor suspects they are related to anti-
TNFa therapy, and are coded using the Medical Dictionary for
Regulatory Activities (MedDRA), V. 6.1. Patients were cate-
gorised as responders or non-responders based on their 6-month
DAS28 scores according to the European League Against
Rheumatism (EULAR) definition.
29 Responders were those
patients who achieved either a EULAR good or moderate
response. Good responders are those patients improving by .1.2
units and achieving an absolute score ,3.2 at 6 months, while
non-responders are those improving ,0.6 and with a 6-month
DAS28 score .5.1. Moderate responders were those falling in
between these definitions.
Patients with new onset psoriasis reported as an adverse
event by the rheumatologist were sent a questionnaire for
further information. Information collected included whether
the patient had prior psoriasis, family history of psoriasis, time
from starting anti-TNFa therapy (or date of registration with
BSRBR for the comparison cohort) to psoriasis onset, extent and
involvement of psoriasis and, if anti-TNFa therapy was stopped
due to the psoriasis, whether the psoriasis subsequently
improved.
Person years were calculated from the first day of anti-TNFa
therapy up to the date of the last follow-up completed up to
July 2007, drug discontinuation or death, whichever occurred
first. The date of drug discontinuation was defined as the date
of the first missed dose.
Patients in the comparison cohort contributed person years
from their date of registration until the date of the last follow-
up completed up to July 2007 or death, whichever came first. All
psoriasis adverse events occurring during this period were
included in the analysis.
All psoriasis adverse events were rheumatologist reported,
and inclusion of patients in this study did not require a separate
dermatological examination or opinion. Only events occurring
while the patient was actively receiving anti-TNF therapy were
attributed to the drug. Rates of psoriasis are presented as
events/1000 person years and 95% CIs. Incidence rates (IR) of
psoriasis within the anti-TNFa treated cohort were compared
by calculating incidence rate ratios (IRR), with stepwise
adjustment for age and gender, then smoking history and
calendar year of registration using Poisson regression with Stata
V. 9.2 (Stata, College Station, Texas, USA).
30
RESULTS
A total of 12 706 patients with RA from the BSRBR were
followed prospectively and included in the analysis. In all, 9826
patients with RA had received anti-TNFa therapy and 2880
were from the comparison cohort, treated using traditional
DMARDs. The median follow-up time was 2.81 years per
person for the anti-TNFa treated cohort and 1.91 years per
person for the comparison cohort. Of patients in the anti-TNFa
treated cohort, 3910 (40%) received etanercept, 3206 (33%)
received infliximab and 2710 (28%) received adalimumab as
their first anti-TNFa therapy.
The baseline characteristics of the patients are described in
table 2. Patients treated with anti-TNFa therapy were
significantly younger, more likely to be female, had longer
disease duration, less likely to have ever smoked and had poorer
Health Assessment Questionnaire (HAQ) and DAS28 scores.
Within the group of patients receiving anti-TNFa therapy, the
adalimumab treated group were slightly older (p=0.005) with
shorter disease duration (p=0.002), included fewer lifelong
non-smokers (p=0.036) and had better HAQ and DAS28 scores
(p,0.001).
By July 2007 there were 42 cases of consultant-reported
psoriasis; 36 (86%) patients returned the questionnaire about
their psoriasis. Five of the six patients that did not return a
questionnaire were actively receiving anti-TNF treatment at the
time of their psoriasis; two patients were receiving etanercept,
two adalimumab and one infliximab. The remaining patient
developed psoriasis 6 months after cessation of infliximab. Of
the 36 patients with reported psoriasis who had returned forms,
9 (25%) were recurrences in patients known to have previous
psoriasis; 27 were incident cases in patients who reported no
previous psoriasis of which 2 occurred in patients who had
discontinued anti-TNFa therapy. The cases of psoriasis reported
after the cessation of anti-TNF therapy (both infliximab)
occurred at 4 months and 6 months following the end date;
the patients had received 15 months and 6 months treatment,
respectively. All 25 incident cases occurred in patients receiving
anti-TNFa therapy and none in the comparison cohort. The
median age of patients with incident psoriasis was 60 (IQR 55
to 63) and the female to male ratio was 5.3:1 (table 3). The
median time from the start of anti-TNF therapy to new onset of
psoriasis was 6 months (range 1–24). Only one patient reported
a positive family history of psoriasis. Of 25 patients, 6 were
good EULAR responders, 13 moderate responders and 6 non-
responders These 25 cases form the content of this analysis. In
order to compare rates of events between the comparison cohort
and the anti-TNFa therapies, one patient from the comparison
cohort was coded at random with psoriasis and included as a
hypothetical reference case.
The crude incidence rate of psoriasis was higher in those
treated with anti-TNFa therapy (1.04 per 1000 person years)
than in the comparison cohort based on 0 cases (one-sided
97.5% CI 0.71 per 1000 person years) in 5207 person years of
follow-up, or a rate calculated using a hypothetical case of
psoriasis (0.19 per 1000 person years) (table 4). The unadjusted
IRR for new onset psoriasis in the patients treated with anti-
TNFa compared to a hypothetical case in the comparison cohort
would be 5.4 (95% CI 0.7 to 40.3).
In all, 13 patients who developed new onset psoriasis were
receiving adalimumab, 6 were receiving infliximab and a further
6 etanercept. Compared to patients in the comparison cohort,
the unadjusted IR for psoriasis in adalimumab treated patients
was significantly higher at 1.84 per 1000 person years (95% CI
0.98 to 3.15) and elevated but not significant for etanercept (IR
0.59, 95% CI 0.22 to 1.28) and infliximab (IR 0.88, 95% CI 0.32
to 1.93) (table 4). Compared to a hypothetical case in the
comparison cohort, the unadjusted IRR for adalimumab would
be significantly higher at 9.6 (95% CI 1.2 to 77.8) and elevated
for etanercept (3.1, 95% CI 0.4 to 25.5) and infliximab (4.6, 95%
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significantly increased risk of psoriasis compared to those
treated with etanercept (IRR 4.6, 95% CI 1.7 to 12.1) and
infliximab (IRR 3.5, 95% CI 1.3 to 9.3) adjusted for age, sex,
smoking status and calendar year of registration.
Of the 25 patients who developed psoriasis while on anti-
TNFa therapy, 8 stopped the drug because of the adverse event.
Six of these patients reported an improvement in their psoriasis
once anti-TNFa therapy was stopped. A total of 13 patients
developed psoriasis within the first 6 months of anti-TNFa
therapy and these patients tended to have extensive psoriasis of
multiple sites or palmoplantar pustulosis (table 3). Eight of
these patients were receiving adalimumab, three infliximab and
two etanercept. Of these 13 patients, 4 stopped anti-TNFa
therapy due to their psoriasis and 3 reported improvement in
their psoriasis after stopping treatment. No information on the
course of skin disease in patients who did not stop treatment
due to the occurrence of psoriasis was available.
DISCUSSION
We have shown that the incidence rate of new onset psoriasis is
elevated in patients with RA treated with anti-TNFa therapy.
No cases of new onset psoriasis were reported in over 5000
person years of follow-up in the patients treated with
traditional DMARD therapy. A hypothetical case was intro-
duced to allow comparison of rates in patients treated with
Table 2 Baseline characteristics of the British Society for Rheumatology Biologics Register (BSRBR) patients with rheumatoid arthritis (RA), by
treatment group
Control (DMARD)
(n=2880)
All anti-TNFa
(n=9826) p Value
Specific anti-TNFa treatment
Etanercept
(n=3910) Infliximab (n=3206)
Adalimumab
(n=2710) p Value
Age, mean (SD) 60.0 (12.4) 56.2 (12.2) ,0.001 55.9 (12.2) 55.9 (12.4) 56.8 (11.9) 0.005
Female, % 72% 76% ,0.001 77% 76% 75% 0.055
Disease duration (years),
median (IQR)
7 (1 to 15) 11 (6 to 19) ,0.001 12 (6 to 19) 12 (6 to 19) 11 (5 to 19) 0.002
Smoking, %:
Current 24% 22% 0.002 21% 22% 24% 0.036
Former 40% 38% 38% 38% 38%
Never 36% 40% 41% 40% 38%
HAQ, median (IQR) 1.6 (1.0 to 2.1) 2.1 (1.8 to 2.5) ,0.001 2.1 (1.8 to 2.5) 2.1 (1.8 to 2.5) 2.0 (1.6 to 2.4) ,0.001
DAS28, mean (SD) 5.0 (1.3) 6.6 (1.0) ,0.001 6.6 (1.0) 6.6 (1.0) 6.5 (1.0) ,0.001
Calendar year, median (IQR) 2004 (2004 to 2005) 2003 (2003 to 2004) ,0.001 2004 (2003 to 2004) 2003 (2002 to 2003) 2004 (2003 to 2005) ,0.001
IQR, interquartile range.
Table 3 Anatomical involvement of new-onset psoriasis (and occurring within 6 months of starting anti-
tumour necrosis factor (TNF) therapy in patients 1–13)
Patient Age/sex Treatment Affected areas
Time to event,
months
Improvement
on stopping
EULAR
responder
1 60/F ETA Elbows and all over body 3 NA Yes
2 63F ETA Not stated 5 NA –
3 56F INF Not stated 5 – –
4 64/M INF Palmoplantar pustulosis 6 NA Yes
5 30/F INF Hairline 6 NA Yes
6 63/F ADA All over, except face 1 Yes No
7 47/M ADA Palmoplantar pustulosis 1 Yes Yes
8 36/F ADA Palmoplantar pustulosis 1 Yes No
9 62/F ADA Back, knees, thighs 1 –* Yes
10 58/F ADA Elbows, ankle 2 NA Yes
11 63F ADA Not stated 3 NA –
12 66/M ADA Right leg and arm 4 NA Yes
13 70F ADA Not stated 4 – –
14 62M ETA Not stated 18 NA –
15 40F ETA Not stated 23 NA –
16 56F ETA Palmoplantar pustulosis 24 Yes Yes
17 33F ETA Body and legs 24 No Yes
18 66F INF Elbows 12 No Yes
19 54F INF Tops of feet and legs 12 NA Yes
20 58F INF Legs, upper arms 18 No Yes
21 56F ADA Palmoplantar pustulosis 10 Yes Yes
22 60F ADA Legs 12 No Yes
23 57F ADA Palmoplantar pustulosis 12 NA –
24 60F ADA Knees 12 NA Yes
25 61F ADA Arms, lower leg, buttocks, face 17 Yes Yes
*Treatment stopped, response unknown.
ADA, adalimumab; EULAR, European League Against Rheumatism; ETA, etanercept; INF, infliximab; NA, not applicable, treatment
was not stopped
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traditional DMARDs. The resulting IRR suggested a fivefold
increase that, although not statistically significant, probably
represents a considerable underestimate of the increased risk in
patients treated with anti-TNF due to the hypothetical ‘‘case’’
in the comparison cohort. Patients with RA treated with
adalimumab had a fourfold increased risk compared to patients
treated with etanercept and a threefold increased risk compared
to patients treated with infliximab. The incidence of psoriasis in
patients treated with adalimumab was 1 new case for every 550
patients treated for a 1-year period, compared to less than 1 new
case for every 5000 patients treated with DMARDs per year.
The temporality and outcome following drug withdrawal point
towards a causal relationship; most psoriasis adverse events
occurred soon after the onset of anti-TNFa therapy and, in
patients whose treatment was subsequently stopped due to
psoriasis, an improvement in psoriasis was experienced.
Our results represent an interesting paradox as anti-TNFa
therapy is now widely used in the management of psoriasis. At
present the molecular mechanisms underlying this are unclear
as TNFa is clearly proinflammatory in human skin and mice
lacking the p75 TNFa receptor have suppressed cutaneous
immune responses.
31 32 However, the implication of this
observation must be that, in this subset of patients who
develop psoriasis, TNFa has an entirely different role than in the
majority of patients.
A number of possible explanations for the paradoxical
occurrence of psoriasis as an adverse event of anti-TNFa
treatment have been explored by other authors. The possibility
of misdiagnosis of the primary rheumatological disease exists, and
psoriatic arthritis may precede psoriasis in approximately 15% of
cases. Alternatively, the patients with psoriasis as an adverse
event may have a genetic predisposition to psoriasis, which after
all is not uncommon (prevalence 2.5%), in addition to their
arthritis.
33 Others have suggested that the adverse event is not
psoriasis but either a drug hypersensitivity reaction such as acute
generalised exanthaematous pustulosis
14 or a bacterial infection
due to the inhibition of TNFa.
15 34 However, neither seems likely.
Thepattern of the psoriaticadverseeventsdonotmatchtheshort
time to onset and rapid spontaneous resolution of acute general-
ised exanthaematous pustulosis
14 35 and biopsies of selected cases
have confirmed typical histological features of psoriasis.
12 18 20 21
None of the patients described by Richtlin etal
34 orKary etal
15 had
experienced a preceding bacterial infection.
If the former explanations are rejected, we must explain
why there is a paradoxical true increase in psoriasis following
anti-TNFa therapy. One hypothesis surrounds the relationship
between TNFa and type 1 interferon (IFN) a, which is a key
player in the pathogenesis of psoriasis. Dermal plasmacytoid
dendritic cells (PDC) which produce IFNa have recently been
shown to have a pivotal role in the early phase of induction of
psoriasis
36 and TNFa down regulates the production of PDC
cells and their synthesis of IFNa.
37 De Gannes et al suggest that
TNFa inhibition may induce locally sustained INFa produc-
tion
20 which in certain patients might lead to an outbreak of
psoriasis and demonstrated lesional type 1 IFNa activity was
increased in patients who developed psoriasis while on anti-
TNFa therapy compared to psoriasis vulgaris. Fiorentino believes
this might also explain why monoclonal antibodies primarily
cause new psoriasis while etanercept may cause flares of pre-
existing disease.
33 Small changes in TNFa such as those associated
withetanerceptmayonlybesufficienttoinduceflares ofpsoriasis
in patients with the disease, while much larger functional
reductions associated with the action of monoclonal antibodies
might be needed to trigger incident cases of psoriasis.
33
This large prospective national observational cohort study
allows us to investigate the apparent relationship between anti-
TNFa therapy and new-onset psoriasis suggested by published
casereports.Themethodologyoftheregisterallowsustocalculate
rates of psoriasis as an adverse event in anti-TNFa treated patients
with RA compared to traditional DMARD therapy and also to
compare rates between specific anti-TNFa drugs.
It is important to consider that this analysis represents an early
analysis based on 1–2 years of follow-up. This study is also based
on low numbers of cases in the patients treated with TNFa,a n d
compared to a hypothetical case of psoriasis in the comparison
cohort where no cases of consultant-reported psoriasis were
identified. This is reflected by the large confidence intervals
around our estimates. Patient follow-up will continue for at least
5 years, and further analysis may allow us to provide more robust
estimates. Psoriasis has also been reported as an adverse event in
other rheumatological conditions such as spondyloarthropathy
21
including ankylosing spondylitis and enteropathic arthritis,
22
Behc ¸et disease and juvenile idiopathic arthritis.
38 Investigation of
the rates of psoriasis adverse events in these groups of patients is
precluded by the low numbers of patients within the BSRBR with
these conditions.
There are however a number of methodological issues that
should be considered in interpreting these results. The first is
the definition of the exposure period-at-risk to anti-TNFa
treatment. We have taken a conservative approach, which limits
the period-at-risk to the time that the patient was actively
Table 4 Comparison of rates of psoriasis by cohort and biological drug compared to disease-modifying antirheumatic drug (DMARD) treatment and
within anti-tumour necrosis factor (TNF) treatments compared with etanercept
Control (DMARD)
(n=2880) Anti-TNF (n=9882)
Specific anti-TNF treatment
Etanercept (n=5265) Infliximab (n=3569) Adalimumab (n=3907)
Person years 5207 23 996 10 167 6782 7047
Follow-up per person, (years) median (IQR) 1.91 (0.96 to 2.45) 2.81 (1.94 to 3.27) 2.95 (2.43 to 3.28) 3.07 (1.99 to 4.04) 1.99 (1.08 to 2.95)
No. of psoriasis 0 25 6 6 13
Rate of psoriasis/1000 person years (95% CI) 0 (0.71{) 1.04 (0.67 to 1.54) 0.59 (0.22 to 1.28) 0.88 (0.32 to 1.93) 1.84 (0.98 to 3.15)
Age-adjusted and sex-adjusted IRR (anti-TNF
treatment only)
NA NA REF 1.50 (0.48 to 4.64) 3.12 (1.05 to 9.28)
Further adjusted for calendar year and smoking NA NA REF 1.30 (0.42 to 4.03) 4.55 (1.72 to 12.05)
Age-adjusted and sex-adjusted IRR (anti-TNF
treatment only)
NA NA 0.67 (0.22 to 2.07) REF 2.08 (0.70 to 6.20)
Further adjusted for calendar year and smoking NA NA 0.77 (0.25 to 2.40) REF 3.51 (1.32 to 9.31)
*Hypothetical case of psoriasis for use as comparison; {one-sided 97.5% confidence interval.
IQR, interquartile range; IRR, incidence rate ratio; NA, not applicable; REF, reference value.
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remains at risk for a lag period after discontinuation of a drug
(which may also vary between drugs), and adverse events
occurring in this period would be missed. The definition of the
period-at-riskbeing the time‘‘ondrug’’ usedinouranalysiswould
underestimate the incidence rate in the anti-TNFa treated cohort
and does not explain our finding of an increased risk.
There are also a number of weaknesses in the case ascertain-
ment and definition. This analysis focuses on non-serious adverse
events and we must acknowledge that we may not have captured
all mild cases of incident psoriasis. Doctors may not detail all non-
serious adverse events in their follow-up forms as they consider
them ‘‘trivial’’ and/or unrelated despite the questionnaires
requesting details of adverse events and not adverse drug
reactions. Therefore, our incident rates are likely to be an under-
estimate. Furthermore, the use of a hypothetical event in the
comparison cohort to generate incident rate ratios will lead to an
underestimate of thetruerateratios between the cohorts.Theuse
of a hypotheticalevent inthe patients treated withDMARDsalso
prevented us presenting adjusted incidence rate ratios because it
would be inappropriate to adjust results according to the
characteristics of an arbitrarily selected patient, therefore the
differences between the patients in the anti-TNF treated and
comparison cohorts cannot be completely accounted for.
It is also possible that psoriasis was preferentially reported in
the anti-TNF treated cohort following the publication of case
reports, thus explaining our positive finding. However, psoriasis
as an adverse event of anti-TNF therapy was not widely
recognised during much of the follow-up period of this study.
Because adalimumab was licensed later than the other two
drugs, a higher proportion of follow-up for patients treated with
adalimumab falls after the initial publications compared with
patients treated with infliximab or etanercept. However,
adjustment for year of entry into the study did not attenuate
our findings. In fact, the point estimate for risk associated with
adalimumab rose to 4.5.
It is possible that there may be some misclassification of the
psoriasis adverse events. Few events had histological confirma-
tion, and inclusion did not require a dermatological opinion.
However, we sought to collect additional detailed information
fromthepatientafterinitialreportsfromthedoctor.Thecaseswe
describe are largely consistent with the case reports of occurrences
of psoriasis following initiation of anti-TNFa in the literature.
CONCLUSIONS
Results from this prospective study support the published case
reports that, paradoxically, the incidence of psoriasis is increased
in patients treated with anti-TNFa therapy. The findings also
suggest that the incidence may be higher in patients treated
with adalimumab.
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